Web Analytics Made Easy - StatCounter
SGLT2 Inhibitors Safer and More Effective Than DPP4s For Heart

SGLT2 Inhibitors Safer and More Effective Than DPP4s For Heart

<

Efficacy Outcomes

Fig 4 Weighted mean difference in change in body weight (kg) from baseline. Inverse variance random effects meta-analysis comparing DPP-4 inhibitors and ...

The exact CV safety for TZDs (pioglitazone), DPP-4 inhibitors, and SGLT2 inhibitors compared to SUs or placebo will be answered in the next few years.

Download figure ...

Figure 1 A summary of the glycemic, cardiovascular, renal, and adverse effects of empagliflozin. Abbreviations: GFR, glomerular filtration rate; HDL, ...

... especially genital tract infections.26 SGLT2 inhibitors are generally considered to be safe in mild to moderate hepatic insufficiency (Table-1).

Download figure ...

... (SGLT2) inhibitors promote glucosuria, thereby reducing glucotoxicity (figurefigure).2x2Drucker ...

Table 2: Summary of sodium-glucose co-transporters

Fig. 2-Change in hemoglobin A1c from baseline to 12, 52, and

www.frontiersin.org

Figure 5 Changes from baseline in 2-hour PPG for patients treated with SGLT2 inhibitors versus placebo. Abbreviations: PPG, postprandial glucose; CI, ...

therapeutic considerations in the pharmacological treatment of diabetes in the elderly and in chronic kidney disease

Figure 1: Flow diagram for study selection and inclusion.

Download figure ...

Fig. 1-Flow diagram of the search. DPP4-I: Dipeptidyl peptidase

Download full-size image

Download figure ...

Effects of Canagliflozin on Cardiovascular, Renal, Hospitalization, and Death Events in the Integrated CANVAS Program.

Download high-res image (607KB) ...

Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors | Diabetes Care

Figure 4 Mean change in body weight. Notes: *p <0.001. ap <0.005 versus SITA. Abbreviations: ERTU, ertugliflozin; SITA, sitagliptin; PBO, placebo.

Download figure ...

... be less in a patient who has progressed to two blood glucose–lowering therapies rather than one. This has yet to be demonstrated in comparative studies.

Management of Type 2 Diabetes: Selecting Amongst Available Pharmacological Agents - Endotext - NCBI Bookshelf

DPP-4 = dipeptidyl peptidase-4; HbA1c = hemoglobin A1c; SGLT-2 = sodium–glucose cotransporter-2.

Download high-res image (576KB) ...

View Hi-Res ...

Fig. 4-The proportion of patients achieving hemoglobin A1c < 7% without hypoglycemia

Download figure ...

Download figure ...

Table 2 Effects of DPP-4 inhibitors and SGLT2 inhibitor on blood pressure, body

Download figure ...

Download figure ...

test Twitter Media - You can prevent or delay the onset of type 2 #diabetes

Fig. 3-Change in FPG and body weight from baseline to 12, 52

Sodium Glucose Transport 2 (SGLT2) Inhibition Decreases Glomerular Hyperfiltration | Circulation

Download figure ...

Abbreviations: CAD, coronary artery disease; CKD, chronic kidney disease; CV, cardiovascular; DPP-4, dipeptidyl peptidase-4; EMPA-REG, EMPAgliflozin, ...

... Download full-size image. Figure 5. SGLT2 inhibition reduces cardiovascular ...

Download high-res image (790KB) ...

Cardiac and Renal Protective Effects of SGLT-2 Inhibitors: Benefits Beyond Glycemic Control

To conclude, in patients with T2DM and mild or moderate RI, EMPA reduced HbA1c, weight, and BP vs PBO, and was well tolerated.

Download figure ...

Structures of C-aryl glucoside SGLT2 inhibitors.

Safety Profile of SGLT2 Inhibitors

Table 8: Effect of SGLT2 inhibitors (SGLT2i) on endogenous glucose production (EGP)

Treating Diabetes Using SGLT2 Inhibitors

Table 2 Case study physical examination and results of laboratory testsa. Note: aSamples for the laboratory tests were drawn 5 days before the office visit.

SGLT2 mRNA and protein expression in cultured renal proximal tubular epithelial cells from T2DM and healthy

Table 7: Results of the met-analysis of 12 head-to-head studies: SUs vs DPP-4I

The 2015 NICE pathway for glucose management in patients with type 2 diabetes is shown in Figure 1, which is also applicable to the management of glucose in ...

Figure 1

Download figure ...

Small

Download figure ...

Download high-res image (186KB) ...

Commentary on abstract 759. Renal safety of SGLT2 inhibitors ...

Download high-res image (337KB) ...

Download figure ...

Efficacy and safety of SGLT2 inhibitors in patients with T2DM

Table 1: FDA communication regarding ketoacidosis with SGLT2 inhibitor therapy

Initial Therapy

6.4; Boxes 6.6 and 6.7), though in a shorter 6-month study (INITIATE, 2007) biphasic aspart 30/70 was more effective than basal glargine.

Comparative PharmacokineticProfile; 8.

Download figure ...

Kidney outcomes were similarly beneficial — this being very important information for me as a kidney specialist. In fact, this was the first new drug since ...

Some Physicians Switch Patients Off Invokana after FDA Warning

Download high-res image (537KB) ...

... of glucose: dependence of rates of filtration, recovery, and excretion on plasma glucose concentration in absence and presence of an SGLT2 inhibitor.

Download figure ...

Download figure ...

A new blood glucose management algorithm for type 2 diabetes: a position statement of the Australian Diabetes Society | The Medical Journal of Australia

TABLE 3 -Combined cardiovascular risk factors

Fig. 1. Formulas for calculating the fractional excretion (FE) and the fractional

Use of antihyperglycaemic drugs with cardiovascular benefit in treating diabetes

Pathophysiology of the relationship between diabetes and frailty (based on Refs. 29 and 74

Download high-res image (331KB) ...

... 3 packs sugar; 24.

... patients who develop statin induced myalgias (SIM), a once weekly statin therapy regimen was found to be well-tolerated and effective for lowering LDL ...

Download figure ...

Metformin performed far better than the insulin/ SU group despite the fact that average blood sugar control was worse.

Sotagliflozin is a dual STLT1 and SGLT2 inhibitor used as adjunct therapy to insulin in patients

Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum | Diabetes Care

Download figure ...

Molecules 21 01136 g002 550

A hemoglobin A1c should be measured every 3 months if therapy is changed or if the A1c is not at goal; it can otherwise be followed every 6 months if at ...

Article Figures & Tables

Download figure ...

Funnel plot reflecting low-level publication bias in the meta-analysis of DPPI-MET vs PBO-MET for evaluating the mean difference in changes from baseline in ...

Side Effects Of SGLT2 Inhibitors

In reality, weighing up each drug is something to do in partnership with a prescriber - guidelines partly drawn up by the American Diabetes Association list ...

Figure 2. Sites of action of the current and potential future pharmacological therapies for the

DPP-4 Inhibitors and Heart Failure: Some Reassurance, Some Uncertainty | Diabetes Care

Even though studies suggest SGLT2 inhibitors may improve cardiovascular outcomes, drugs in this class are not FDA approved for CV risk reduction.